Blood filtering for NMOSD attacks
Treatments studied
Part of Brain & nervous system, Eyes & vision, Immune system & allergy clinical trials.
This trial tests a blood filtering procedure called Protein A immunoadsorption for people having an acute episode of neuromyelitis optica spectrum disorder (NMOSD). It may help remove harmful antibodies from your blood and reduce symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with NMOSD and are currently having an acute attack
- You are between 18 and 65 years old
- You have tested positive for AQP4 antibodies using a special blood test
- You are not pregnant or breastfeeding
- You have not used certain immune treatments (like monoclonal antibodies) in the last 3 to 6 months
- You do not have severe bleeding problems, heart failure, or active serious infections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine (NouvSoma001) for people with neuromyelitis optica (NMOSD) who are having a flare-up. The goal is to see if the treatment is safe and if it helps reduce symptoms like pain and trouble moving.
This trial tests a new medication called JYP0061 for people with NMOSD who are currently experiencing a sudden worsening of symptoms (acute attack). It aims to see if the drug can help control the attack and improve outcomes.
This study uses MRI scans to look for hidden disease activity in people with NMOSD who feel stable and are already on rituximab. The goal is to catch any signs of damage early, which might help prevent future disability.
This trial tests a new antibody-based medicine to help people recover from an acute attack of neuromyelitis optica spectrum disorder (NMOSD), a condition that causes inflammation in the eyes and spinal cord. If you are having a recent flare-up and are already getting or planning to get steroid treatment, this study might offer an additional option to reduce damage and speed recovery.
This trial tests a new treatment called modified zipper therapy for people with neuromyelitis optica spectrum disorder (NMOSD) who have a specific antibody (AQP4-IgG) in their blood. It aims to stop a recent attack and improve recovery.
This study tests a new treatment called CC-97540 (a type of CAR T-cell therapy) for people with neuromyelitis optica spectrum disorder (NMOSD), which is an autoimmune disease that affects the eyes and spinal cord. The goal is to see if this treatment is safe and tolerable.
Hear when a new Neuromyelitis Optica Spectrum Disorders trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.